Diabetes drug shows promise for sleep apnea in tiny trial

NCT ID NCT07281196

Completed Symptom relief Sponsor: Shanghai Fengxian District Central Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study tested whether semaglutide, a drug used for type 2 diabetes and weight loss, could improve sleep apnea in 15 people with diabetes or obesity. Researchers measured breathing pauses during sleep (AHI) after 1 and 4 weeks of treatment. The goal was to see if the drug might offer a new option for managing sleep apnea, but the study was very small and lacked a comparison group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (a once-weekly injection for diabetes and weight loss)
What this could lead to: If it works, this could point toward a new way to ease sleep apnea symptoms in people with diabetes or obesity.
What could go wrong: This was a very small study (15 people) with no placebo group, so results may not be reliable or apply to everyone. It only looked at short-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic syndrome X obesity disorder obstructive sleep apnea syndrome sleep apnea syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLEEP APNEA SYNDROME (OSAS)

Contacts and locations

Locations

Shanghai Fengxian District Central Hospital

Shanghai, 201499, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.